Remibrutinib, a BTKi, has no impact on serum immunoglobulin levels: Insights from chronic spontaneous urticaria

Authors
Category Primary study
Conference10th Congress of the European Academy of Neurology
Year 2024
This article has no abstract
Epistemonikos ID: 3e1e7ea7bb5503c2465cb96ce310a855a7f870a8
First added on: Jan 10, 2026